Short Interest in Aravive Inc (NASDAQ:ARAV) Decreases By 13.8%

Aravive Inc (NASDAQ:ARAV) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 20,700 shares, a decrease of 13.8% from the May 30th total of 24,000 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average daily volume of 15,100 shares, the short-interest ratio is currently 1.4 days.

Several analysts recently commented on ARAV shares. Wedbush set a $269.00 target price on shares of United Therapeutics and gave the company a “buy” rating in a research note on Monday, April 8th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Piper Jaffray Companies increased their target price on shares of Boot Barn from $33.00 to $41.00 and gave the company an “overweight” rating in a research note on Monday, May 13th. Finally, Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday.

ARAV stock opened at $6.00 on Friday. Aravive has a 52-week low of $3.07 and a 52-week high of $12.90. The company’s 50 day moving average price is $5.93. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.78 and a quick ratio of 7.78. The firm has a market capitalization of $66.52 million, a price-to-earnings ratio of -0.56 and a beta of 2.30.

Aravive (NASDAQ:ARAV) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.44. The firm had revenue of $1.70 million for the quarter. Equities research analysts predict that Aravive will post -2.19 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in ARAV. Northern Trust Corp acquired a new stake in shares of Aravive during the fourth quarter valued at approximately $54,000. California Public Employees Retirement System acquired a new stake in shares of Aravive during the fourth quarter valued at approximately $57,000. Acadian Asset Management LLC acquired a new stake in shares of Aravive during the fourth quarter valued at approximately $60,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Aravive during the fourth quarter valued at approximately $73,000. Finally, Deutsche Bank AG acquired a new stake in shares of Aravive during the fourth quarter valued at approximately $78,000. Institutional investors and hedge funds own 27.57% of the company’s stock.

Aravive Company Profile

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Further Reading: How do candlesticks reflect price movement?

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply